Oncology-related issues of angiotensin-receptor blockers-Reference-Cited by-同舟云学术

Oncology-related issues of angiotensin-receptor blockers

Published:2015-03 Issue:11 Volume:156 Page:423-430
ISSN:0030-6002
Container-title:Orvosi Hetilap
language:hu
Short-container-title:Orvosi Hetilap

Author:

Telekes András¹,Kiss István²³⁴

Affiliation:

1. Bajcsy-Zsilinszky Kórház Onkológiai Osztály Budapest Maglódi út 89–91. 1106

2. Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika, Geriátriai Tanszéki Csoport Budapest

3. Szent Imre Egyetemi Oktatókórház Nephrologia-Hypertonia Profil és Aktív Geriátriai Részleg Budapest

4. B. Braun Avitum Zrt. Dialízis Hálózat 1. Sz. Dialízisközpont Budapest

Abstract

Recently controversial data emerged regarding the cancer inducing activity of angiotensin-receptor blockers. There may be several reasons which may explain the controversial data published in the scientific literature including wrong trial design or misinterpretation of data. Considering the large number of patients receiving treatment for hypertension, it is essential to have a clear view of the cancer-related safety of these drugs. This paper tries to give an overview on this issue based on data available in the literature. According to our present knowledge, angiotensin-receptor blockers exert more likely anticancer activity rather than carcinogenesis inducing effect. In fact, some oncologic trials point to this direction, because angiotensin-receptor blockers are suggested as co-treatment to chemotherapy in cases of pancreatic, oesophageal and gastric cancers. Orv. Hetil., 2015, 156(11), 423–430.

Publisher

Akademiai Kiado Zrt.

Subject

General Medicine

Link

https://www.akademiai.com/doi/pdf/10.1556/OH.2015.30118

Reference62 articles.

1. Lawes, C. M., Vander Hoorn, S., Rodgers, A.: Global burden of blood-pressure-related disease, 2001. Lancet, 2008, 371(9623), 1513–1518.

2. Globocan 2008. Cancer incidence and mortality worldwide. WHO, International Agency for Research on Cancer. http://www.iarc.fr/en/media-centre/iarcnews/2010/globocan2008.php

3. Globocan 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. WHO, International Agency for Research on Cancer. http://globocan.iarc.fr/Default.aspx

4. Kiss, I., Telekes, A.: Cancer and hypertension. In: Farsang, Cs. (ed.): Textbook of hypertension. [Daganatos betegségek és hypertonia. In: Farsang, Cs. (szerk.): A hypertonia kézikönyve.] Medintel Kiadó, Budapest, 2002. [Hungarian]

5. Sipahi, I., Debanne, S. M., Rowland, D. Y., et al.: Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol., 2010, 11(7), 627–636.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glycative stress from advanced glycation end products (AGEs) and dicarbonyls: An emerging biological factor in cancer onset and progression;Molecular Nutrition & Food Research;2016-02-25